Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
CC transcript
Inv. presentation
Employment agrmnt
TITAN PHARMACEUTICALS INC (TTNP) Create: Alert

All | News | Filings
Date FiledTypeDescription
07/07/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
06/29/2023 8-K Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits  Interactive Data
06/06/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and...
03/22/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
02/09/2023 8-K Shareholder Nominations Pursuant to Exchange Act Rule 14a-11, Financial Statements and Exhibits  Interactive ...
01/06/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and...
12/15/2022 8-K Quarterly results
12/12/2022 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "LICENSE AGREEMENT between TITAN PHARMACEUTICALS, INC. and OCULAR THERAPEUTIX, INC.",
"Titan Pharmaceuticals Announces Licensing Agreement with Ocular Therapeutix"
09/21/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "THIS STAND-ALONE STOCK OPTION AGREEMENT dated as of the 15 th day of September, 2022 by and between Titan Pharmaceuticals, Inc., a Delaware corporation , and [●] ."
08/22/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/16/2022 8-K Quarterly results
08/05/2022 8-K Quarterly results
07/22/2022 8-K Quarterly results
07/13/2022 8-K Quarterly results
07/11/2022 8-K Quarterly results
07/05/2022 8-K Quarterly results
06/02/2022 8-K Quarterly results
05/06/2022 8-K Quarterly results
02/03/2022 8-K Quarterly results
12/29/2021 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "AMENDMENT TO THE BYLAWS OF TITAN PHARMACEUTICALS, INC."
12/22/2021 8-K Submission of Matters to a Vote of Security Holders, Other Events  Interactive Data
12/14/2021 8-K Quarterly results
11/09/2021 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Sustained anti-pruritic effect in mice with TP- 2021, a kappa opioid agonist peptide, delivered by subdermal ProNeura® Implants B. B. Land1, S. Sreedharan2, R. Patel2, T. Beck3, K. DeVarney2, M. Rubin2, *C. Chavkin1; 1Pharmacol., Univ. of Washington, Seattle, WA; 2Titan Pharmaceuticals, South San Francisco, CA; 3Med. Univ. of South Carolina, Charleston, SC",
"SUSTAINED ANTI-PRURITIC EFFECT OF TITAN’ S TP-2021 IMPLANT REPORTED TODAY AT NEUROSCIENCE 2021 SOUTH SAN FRANCISCO, CA – November 8, 2021 – Titan Pharmaceuticals, Inc. announced that, in a presentation given today at the Society for Neuroscience 2021 Meeting, Ben Land, Ph.D., Research Assistant Professor at the University of Washington’ s Department of Pharmacology, reported additional positive data from an ongoing in vivo study of its human kappa-opioid receptor agonist ProNeura-based implant in an established 5'-guanidinonaltrindole itch-induced mouse model. As previously reported , low dose TP-2021 implants had demonstrated anti-pruritic effects for up to 2 weeks in this model. Higher-dose TP-2021 implants were subsequently formulated and the study repeated after content analysis of th..."
07/26/2021 8-K Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits
Docs: "Letter from OUM & Co., LLP to the Securities and Exchange Commission"
02/04/2021 8-K Quarterly results
01/19/2021 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...
Docs: "Form of Warrant",
"Opinion of Loeb & Loeb LLP",
"Form of Securities Purchase Agreement",
"Placement Agency Agreement",
"Titan Pharmaceuticals Announces Pricing of $9.7 Million Registered Direct Offering"
01/08/2021 8-K Quarterly results
12/30/2020 8-K Submission of Matters to a Vote of Security Holders, Other Events
12/03/2020 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
12/01/2020 8-K Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...
Docs: "Certificate of Amendment to the Restated Certificate of Incorporation",
"Titan Pharmaceuticals Announces Reverse Stock Split"
11/02/2020 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Underwriting Agreement between Titan Pharmaceuticals, Inc. and Maxim Group LLC",
"Titan Pharmaceuticals Announces Pricing of $8.0 Million Underwritten Public Offering",
"TITAN PHARMACEUTICALS COMPLETES DEBT SETTLEMENT WITH MOLTENI AND HORIZON & ACQUISITON OF JT PHARMA’ S KAPPA OPIOID AGONIST PEPTIDE, JT-09"
10/28/2020 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "TITAN PHARMACEUTICALS ENTERS INTO DEFINITIVE AGREEMENT TO ACQUIRE JT PHARMA’ S KAPPA OPIOID AGONIST PEPTIDE, JT-09"
10/26/2020 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Debt Settlement and Release Agreement",
"Stephen Kilmer Investor Relations"
10/15/2020 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy